Download PDF
Geburtshilfe Frauenheilkd 2002; 62(12): 1155-1161
DOI: 10.1055/s-2002-36363
Übersicht

Georg Thieme Verlag Stuttgart · New York

Von der Pathophysiologie und Prävention des ovariellen Überstimulationssyndroms (OHSS) bis zur stadiengerechten Therapie

From the Pathophysiology and Prevention of the Ovarian Hyperstimulation Syndrome (OHSS) to Therapy Strategies - An OverviewS. Kissler 1 , 2 , E. Siebzehnrübl 1 , 2 , M. Kaufmann 2
  • 1Schwerpunkt Gynäkologische Endokrinologie und Reproduktionsmedizin der Klinik für Gynäkologie und Geburtshilfe, Johann-Wolfgang-Goethe-Universität Frankfurt am Main
  • 2Klinik für Gynäkologie und Geburtshilfe, Johann-Wolfgang-Goethe-Universität Frankfurt am Main
Further Information

Publication History

Publication Date:
20 December 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das schwere ovarielle Überstimulationssyndrom (OHSS) kompliziert 0,3 - 5 % der Zyklen kontrollierter ovarieller Stimulation im Rahmen assistierter reproduktiver Techniken (ART). Obwohl die Ursachen des OHSS nicht endgültig geklärt sind, löst das zur Ovulationsinduktion gegebene HCG oder die endogene HCG-Produktion beim Eintritt einer Schwangerschaft das OHSS aus. Es erfolgt eine vermehrte Neoangiogenese und erhöhte Kapillarpermeabilität im Bereich der Ovarien, so dass es lokal zu einem vermehrten Flüssigkeitsübertritt aus den Ovarien in die Bauchhöhle als Aszites kommt, beim schweren OHSS verläuft die Erkrankung durch die erhöhte Gefäßpermeabilität meist systemisch. Die wichtigsten Faktoren, die auf zellulärer Ebene für das Entstehen eines OHSS verantwortlich gemacht werden, sind das Angiotensin-Renin-Aldosteron-System, Zytokine (IL-1, IL-2, IL-6, IL-8), der Tumornekrosefaktor alpha (TNF-α) und in zentraler Rolle der Vascular endothelial growth factor (VEGF). Da in supprimierten Stimulationszyklen die Ovulationsinduktion derzeit nur mit HCG ausgelöst werden kann, lässt sich das OHSS trotz verschiedener Ansätze der Prävention nicht komplett vermeiden. Deshalb möchten wir in dieser Arbeit eine Übersicht der stadienadaptierten Therapie vorstellen.

Abstract

Severe ovarian hyperstimulation syndrome (OHSS) complicates 0.3 - 5 % of controlled ovarian stimulation cycles for assisted reproductive techniques (ART). Although the reasons for OHSS still remain enigmatic, HCG either applicated for ovulation induction or produced by the trophoblast is the most important trigger for developing OHSS. Enhanced neoangiogenesis and capillary permeability in the ovaries cause a third space fluid shift which locally results in ascites or pleural effusion reflecting systemic severe OHSS. The most important factors which are involved in the development of OHSS on the cellular level are the angiotensin-renin-aldosteron-system, cytokines (IL-1, IL-2, IL-6, IL-8), tumor necrosis factor alpha (TNF-α) and of central importance vascular endothelial growth factor (VEGF). As OHSS cannot completely be prevented in down-regulated stimulation cycles, this article can be regarded as a guideline for adequate therapy strategies depending upon the grade of OHSS.

Schlüsselwörter

OHSS - Prävention - Therapie - Kapillarpermeabilität - Zytokine

Key words

OHSS - Prevention - Therapy - Capillary permeability - Cytokines

Literatur

  • 1 Aboulghar M, Evers J H, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome.  Cochrane Database Syst Rev. 2000;  2 CD001302
    PubMedGoogle Scholar
  • 2 Abramov Y, Schenker J G, Lewin A. et al . Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome.  Hum Reprod. 1996;  11 1381-1386
    PubMedGoogle Scholar
  • 3 Abramov Y, Barak V, Nisman B, Schenker J G. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.  Fertil Steril. 1997;  67 261-265
    CrossrefPubMedGoogle Scholar
  • 4 al-Shawaf T, Zosmer A, Hussain A, Tozer A, Panay N, Wilson C, Lower A M, Grudzinskas J G. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified “coasting” strategy based on ultrasound for identification of high-risk patients.  Hum Reprod. 2001;  16 24-30
    CrossrefPubMedGoogle Scholar
  • 5 Araujo E, Bernardini L, Frederick J L. Prospective randomized comparison of human chorionic gonadotrophin versus intramuscular progesterone for luteal-phase support in assisted reproduction.  J Assist Reprod Genet. 1994;  11 74-78
    CrossrefPubMedGoogle Scholar
  • 6 Blumenfeld Z, Lang N, Amit A. et al . Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.  Fertil Steril. 1994;  62 456-460
    PubMedGoogle Scholar
  • 7 Chen C D, Wu M Y, Yang J H. et al . Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.  Fertil Steril. 1998;  68 287-291
    PubMedGoogle Scholar
  • 8 Claman P, Domingo M, Leader A. et al . Luteal-phase support in an in-vitro fertilization program using gonadotropin-releasing hormone analogue (GnRHa) before superovulation.  Hum Reprod. 1992;  7 487-491
    PubMedGoogle Scholar
  • 9 Der-Chen C, Fu-Chen H, Fen-Lu H. et al . Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome.  Hum Reprod. 2000;  15 1037-1042
    CrossrefPubMedGoogle Scholar
  • 10 Egbase P E, Al-Sharhan M, Grudzinskas J G. Early unilateral follicular aspiration compared to coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study.  Hum Reprod. 1999;  14 1421-1425
    CrossrefPubMedGoogle Scholar
  • 11 Egbase P E, Makhseed M, Al Sharhan M, Grudzinskas J G. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotropin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro-fertilization: a prospective randomised study.  Hum Reprod. 1997;  12 2603-2606
    CrossrefPubMedGoogle Scholar
  • 12 Egbase P E, Al-Sharhan M, Berlingieri P, Grudzinskas J G. Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment.  Hum Reprod. 2000;  15 2082-2086
    CrossrefPubMedGoogle Scholar
  • 13 Elchalal U, Schenker J G. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas.  Hum Reprod. 1997;  12 1129-1137
    CrossrefPubMedGoogle Scholar
  • 14 Gerris J, De-Vits A, Joostens M, Van-Royen E. Triggering of ovulation-induction in human menopausal gonadotropin-stimulated cycles: comparison between intravenously administered gonadotropin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotropin (10, 000 IU).  Hum Reprod. 1995;  10 56-62
    CrossrefPubMedGoogle Scholar
  • 15 Felberbaum R, Reissmann T, Küpker W, Diedrich K. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonist (Cetrorelix) in women with tubal infertility.  Eur J Obstet Gynecol Reprod Biol. 1995;  61 151-155
    CrossrefPubMedGoogle Scholar
  • 16 Ferraretti A P, Gianaroli L, Magli C, Fortini D, Selman H A, Feliciani E. Elective cryopreservation of all pronucleate embryos in woman at risk of ovarian hyperstimulation syndrome: efficiency and safety.  Hum Reprod. 1999;  14 1457-1460
    CrossrefPubMedGoogle Scholar
  • 17 Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Capsi E. Ovarian hyperstimulation syndrome: an update review.  Obstet Gynecol. 1989;  44 430-440
    PubMedGoogle Scholar
  • 18 Hack C E, DeGroot E R, Felt-Bersma R JF. Increased plasma levels of interleukin-6 in sepsis.  Blood. 1989;  74 1704-1710
    PubMedGoogle Scholar
  • 19 Haning R V, Srawn E Y, Nolten W E. Pathophysiology of the ovarian hyperstimulation syndrome.  Obstet Gynecol. 1985;  66 882-889
    PubMedGoogle Scholar
  • 20 Jäger W, Wildt L, Lang N. Ovarian hyperstimulation syndrome. Hafez ESE Assisted Human Reproductive Technology. 1991: 61-75
    Google Scholar
  • 21 Kodama H, Fukuda J, Karube H, Matsui T, Shimizu Y, Tanaka T. Characteristic of blood hemostatic markers in a patient of ovarian hyperstimulation syndrome who actually developed thromboembolism.  Fertil Steril. 1995;  64 1207-1209
    PubMedGoogle Scholar
  • 22 Keck C, Neulen J, Breckwoldt M. Das ovarielle Hyperstimulationssyndrom.  Geburtsh Frauenheilk. 1994;  54 315-320
    PubMedGoogle Scholar
  • 23 Kissler S, Neidhardt B, Siebzehnruebl E, Schmitt H, Tschaikowsky K, Wildt L. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation sydrome - a case report.  Eur J Obstet Gynecol. 2001;  99 131-134
    CrossrefPubMedGoogle Scholar
  • 24 Knox G E. Antihistamine blockade of the ovarian hyperstimulation syndrome.  Am J Obstet Gynecol. 1974;  118 992-994
    PubMedGoogle Scholar
  • 25 Krasnow J S, Berga S L, Gusick D S. et al . Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome - a preliminary report.  Fertil Steril. 1996;  65 552-555
    PubMedGoogle Scholar
  • 26 Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of GnRH-analogues and HCG for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case control-study.  Hum Reprod. 1996;  11 1399-1402
    PubMedGoogle Scholar
  • 27 Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF.  Acta Obstet Gynaecol Scand. 2001;  80 in press
    PubMedGoogle Scholar
  • 28 Ludwig M, Felberbaum R E, Devroey P, Albano C, Riethmüller-Winzen H, Schüler A, Engel J, Diedrich K. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix in controlled ovarian stimulation for assisted reproduction.  Arch Gynecol Obstet. 2000;  264 29-32
    CrossrefPubMedGoogle Scholar
  • 29 Ludwig M, Finas A, Katalinic A, Strik D, Kowalcek I, Schwartz P, Felberbaum R, Kupker W, Schopper B, Al-Hasani S, Diedrich K. Prospective, randomized study to evaluate the success rates using HCG, vaginal progesterone or a combination of both for luteal support.  Acta Obstet Gynaecol Scand. 2001;  80 574-582
    PubMedGoogle Scholar
  • 30 Ludwig M, Bauer O, Lopens A, Jelkmann W, Diedrich K. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome.  Hum Reprod. 1998;  13 30-32
    CrossrefPubMedGoogle Scholar
  • 31 Meirow D, Schenker J G, Rosler A. Ovarian hyperstimulation syndrome with low oestradiol in non-classic 17 alpha-hydroxylase, 17, 20-lyase deficiency: What is the role of oestrogens?.  Hum Reprod. 1996;  11 2119-2121
    PubMedGoogle Scholar
  • 32 Morris R S, Wong I L, Kirkman E. et al . Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome.  Hum Reprod. 1995;  10 1355-1358
    PubMedGoogle Scholar
  • 33 Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, Serr D M. et al . Thromboembolic phenomena after ovarian stimulation with human gonadotrophins.  Lancet. 1965;  2 1213-1215
    PubMedGoogle Scholar
  • 34 Navot D, Margalioth E J, Laufer N. Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome.  Fertil Steril. 1987;  48 57-61
    PubMedGoogle Scholar
  • 35 Neulen J, Yan Z, Raczek S. et al . Human chorionic gonadotropin-dependant expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.  J Clin Endocrinol Metabol. 1995;  80 1967-1971
    CrossrefPubMedGoogle Scholar
  • 36 Neulen J. Das ovarielle Überstimulationssyndrom.  Geburtsh Frauenheilk. 2001;  61 XLI-XLIII
    PubMedGoogle Scholar
  • 37 Neulen J. Reproduktionsmedizin. Keck C, Neulen J, Breckwoldt M Endokrinologie, Reproduktionsmedizin, Andrologie. 1. Aufl. Stuttgart; Thieme 1997: 132-135
    Google Scholar
  • 38 Okusawa S, Gelfand J, AIkefima T. et al . Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.  J Clin Invest. 1988;  81 1162-1172
    PubMedGoogle Scholar
  • 39 Olivennes F. Induction of final oocyte maturation by a single dose of GnRH agonist after Ganirelix treatment.  Gynecol Endocrinol. 2001;  15 (Suppl 1) 7
    PubMedGoogle Scholar
  • 40 Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotrophin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH-antagonist.  Fertil Steril. 1996;  66 151-153
    PubMedGoogle Scholar
  • 41 Quenaan J TJ, Veeck L L, Toner J P, Oehninger S, Muasher S J. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers.  Hum Reprod. 1997;  12 1573-1576
    CrossrefPubMedGoogle Scholar
  • 42 Ravindranath N, Little-Ihrig L, Phillips H S. Vascular endothelial growth factor mRNA expression in the primate ovary in relation to follicular growth and corpus luteum function.  Endocrinol. 2001;  2065 254-260
    PubMedGoogle Scholar
  • 43 Rimington M R, Walker S M, Shaw R W. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilisation treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries.  Hum Reprod. 1997;  12 1443-1447
    CrossrefPubMedGoogle Scholar
  • 44 Schenker J G, Polishuk W Z. Ovarian hyperstimulation syndrome.  Obstet Gynecol. 1975;  46 23-28
    PubMedGoogle Scholar
  • 45 Schenker J G, Polishuk W Z. The role of prostaglandins in ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 1976;  6 47-52
    CrossrefPubMedGoogle Scholar
  • 46 Schwartz M, Jewelewicz R. The use of gonadotropins for induction of ovulation.  Fertil Steril. 1981;  35 3-12
    PubMedGoogle Scholar
  • 47 Senger D R, Galli S J, Dvorak A M. et al . Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.  Science. 1983;  219 983-985
    CrossrefPubMedGoogle Scholar
  • 48 Shaker A G, Zosmer A, Dean N, Bekir J S, Jacobs H S, Tan S L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome.  Fertil Steril. 1996;  65 992-996
    PubMedGoogle Scholar
  • 49 Sher G, Zouves C, Feinman M, Maassarani G. “Prolonged coasting”: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilisation.  Hum Reprod. 1995;  10 3107-3109
    PubMedGoogle Scholar
  • 50 Thaler I, Yoffe N, Kaftory J K, Brandes J M. Treatment of ovarian hyperstimulation syndrome: the physiological basis for a modified approach.  Fertil Steril. 1981;  36 110-113
    PubMedGoogle Scholar
  • 51 Watson J M, Sensintaffar F L, Berek J S, Martinez-Masa O. Constitutive production of IL-6 by ovarian cancer cell-lines and by primary ovarian tumor cultures.  Cancer Res. 1990;  50 6959-6965
    PubMedGoogle Scholar
  • 52 World Health Organization . Agents stimulating gonadal function in humans.  WHO Techn Rep Series. 1973;  514
    PubMedGoogle Scholar
  • 53 Zaides I, Friedman M, Lindenbaum E S. et al . Serotonin and the ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 1983;  15 55-61
    CrossrefPubMedGoogle Scholar

Dr. med., Oberarzt Schwerpunkt Gynäkologische Endokrinologie und Reproduktionsmedizin Stefan Kissler

Klinik für Gynäkologie und Geburtshilfe, Johann-Wolfgang-Goethe-Universität

Theodeor-Stern-Kai 7

60590 Frankfurt/Main

Email: stefan.kissler@kgu.de

      >